» Articles » PMID: 39384699

Harnessing Phytochemicals to Regulate Catalytic Residues of Alpha-Amylase and Alpha-Glucosidase in Type 2 Diabetes

Abstract

Type 2 diabetes (T2D), also known as non-insulin-dependent diabetes mellitus, represents the prevailing manifestation of diabetes, encompassing a substantial majority of cases, ~90-95%. Plant-derived antidiabetic leads are being intensively explored due to their safety and effectiveness. The main objective of the present study is to evaluate the anti-diabetic potential of the traditional formulation Karisalai Karpam through in-vitro and in-silico investigations. The in-vitro and in-silico investigation of traditional polyherbal preparation Karisalai Karpam (KK) chooranam were performed to ascertain its inhibitory potential against α-amylase and α-glucosidase enzymes along with antioxidant (DPPH and ABTS) and phytochemical analysis. The results of enzyme inhibitory activity of KK witnessed highest activity against α-glucosidase enzyme with a percentage inhibition of 84.66 ± 2.50% (IC,187.9 ± 5.79 μg/ml) followed by moderate level of α-amylase inhibition exhibited with 72.94 ± 3.66% (IC, 241.6 ± 9.76 μg/ml). Additionally, the strongest antioxidant activity was observed in quenching DPPH (IC,154.8 ± 14.53 μg/ml) and ABTS radicals (IC,148.6 ± 29.74 μg/ml). The outcome of the molecular docking studies indicated that among the 17 compounds analysed, the lead such as acalyphin, apigenin, humulene, and indirubin exhibited a prominent binding affinity over the residual binding site of α-glucosidase. It's important to note that the catalytic site of the enzyme α-amylase is primarily occupied by amyrin, apigenin, arjunolic acid, β-sitosterol, geraniol, and tricetin. In conclusion, the formulation KK demonstrates robust alpha-glucosidase and alpha-amylase inhibitory activity. It's also worth noting that the formulation exhibits noteworthy antioxidant properties, which could provide additional health benefits. The binding mode and energies of the identified phytochemicals against the target enzymes further support the formulation's antidiabetic potential.

References
1.
Heise T, Nosek L, Ronn B, Endahl L, Heinemann L, Kapitza C . Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6):1614-20. DOI: 10.2337/diabetes.53.6.1614. View

2.
Ahmed Q, Ali A, Mukhtar S, Alsharif M, Parveen H, Mohmad Sabere A . Medicinal Potential of Isoflavonoids: Polyphenols That May Cure Diabetes. Molecules. 2020; 25(23). PMC: 7727648. DOI: 10.3390/molecules25235491. View

3.
Zheng P, Xiong Z, Liao C, Zhang X, Feng M, Wu X . and studies of bis (indol-3-yl) methane derivatives as potential α-glucosidase and α-amylase inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1):1938-1951. PMC: 8409970. DOI: 10.1080/14756366.2021.1971976. View

4.
Dhital S, Lin A, Hamaker B, Gidley M, Muniandy A . Mammalian mucosal α-glucosidases coordinate with α-amylase in the initial starch hydrolysis stage to have a role in starch digestion beyond glucogenesis. PLoS One. 2013; 8(4):e62546. PMC: 3636141. DOI: 10.1371/journal.pone.0062546. View

5.
van de Laar F, Lucassen P, Akkermans R, van de Lisdonk E, Rutten G, van Weel C . Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2004; 28(1):154-63. DOI: 10.2337/diacare.28.1.154. View